The present study preliminarily revealed the pharmacological mechanism of HXTLF in treating vasculitis using network pharmacology and in vitro experiments, implying that HXTLF might treat vasculitis by regulating AKT to inhibit the formation of NETs and induce IL-1β production in cells. This evidence concerns the gene IL1B and vasculitis.